CTC Bio씨티씨바이오

CTC Bio has returned to a profit on a trailing basis after losses in 2023 and 2024, but its shares are down 44.6% over the past year.

CTC Bio, a Korean pharmaceutical maker with animal and human medicine businesses, reported trailing twelve-month revenue of ₩122B and operating income of ₩11B to H1 2026, a 9.4% operating margin. Its 2025 revenue fell 14.3% to ₩124B, though operating income recovered to ₩6.2B from a loss the year before. The shares closed at ₩2,925 on 2026-10-19, near the lower half of their 52-week range of ₩2,570 to ₩5,610.

What stands out

• Trailing operating margin of 9.4% and net margin of 6.1% are well above the 2023 and 2024 losses shown in the annual figures.
• Annual revenue has been volatile: up 17.7% in 2022, down 16.5% in 2023, up 4.7% in 2024, then down 14.3% in 2025.
• Trailing free cash flow of about ₩7.2B and cash of about ₩21.9B are shown, with no borrowings reported in the data.
• Valuation metrics are low against the sector: P/E of 9.4 and P/B of 0.9, compared with peers such as Yuhan at 27.1 P/E and Celltrion at 29.2 P/E. The data does not explain the reason for this gap.
• Recent filings are routine in nature, including the H1 2026 half-year report, the Q1 2026 quarterly report, and the annual general meeting results; no news headlines were supplied.

What to watch

• The next periodic filings and whether revenue and operating income keep the recent recovery going, since 2025 revenue declined.
• Foreign ownership is small at 1.9%, and the 20-day flows show retail investors net sellers while foreign investors were net buyers; changes in these flows are worth tracking.
• The data gives no analyst views, forecasts or fair value estimate, so the outlook beyond reported figures is not known from this information.